F Rosina

Presidio Sanitario San Camillo, Torino, Torino, Piedmont, Italy

Are you F Rosina?

Claim your profile

Publications (197)1189.49 Total impact

  • Giovanni C Actis · Rinaldo Pellicano · Floriano Rosina ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the level of sophistication they have reached nowadays, the available tools for treatment of inflammatory bowel disease (IBD) can at best chronicize the disease but not cure it. Chances to make leap forward from this hold-back may include designs to reach personalized treatment strategies taking advantage of modern genome associated studies, and shift resources towards unfolding inciting pathogenetic steps rather than continuing to develop drugs that address down-stream phenomena. We have arbitrarily chosen to scrutinize a few projects that may make their way in 2015 and mark the history of IBD research. The list includes: the role of appendix as a regulating factor in pathogenesis of ulcerative colitis/proctitis; the reappraisal of (auto)immune phenomena in the era of microbiome; projects to treat IBD by stem cell infusion; recognition of the crucial pathogenetic role of gut microbiome, and attempts to modify it to treat enteric diseases, from clostridium difficile infection to IBD.
    05/2015; 6(2):10-6. DOI:10.4292/wjgpt.v6.i2.10
  • Giovanni Clemente Actis · Floriano Rosina · Rinaldo Pellicano ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Dear EditorThe prevalence of ulcerative proctitis has increased by threefold between 1965 and 1983, accounting for between 17 and 49 % of all ulcerative colitis (UC) cases and making 70 % of the out-patients. Its management remains a challenge. Local and/or systemic aminosalicylates were said to attain a 78 % response rate, but this figure has recently fallen to the low 40 % in our hands. As a non-pharmacologic treatment, appendectomy has recently received attention, on the basis of previous claims of its protective effect against the onset of UC. We describe a case of recalcitrant proctitis merging with a few challenging co-morbidities and discuss the role that was played by the appendectomy option in these specific premises.The case was a 48-year-old Caucasian male who had three siblings with a history of partial thyroidectomy for undefined diagnosis. He had been a “healthy” hepatitis B s antigen (HBsAg) carrier since 1995 and had undergone an initial endoscopy for hematochezia in Fe ...
    International Journal of Colorectal Disease 02/2015; DOI:10.1007/s00384-015-2158-1 · 2.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis is an extremely rare condition that has been reported in only six published cases so far. Here we report two cases showing the clinical manifestations of both primary biliary cirrhosis and primary sclerosing cholangitis. In one case the overlap condition was associated with psoriatric arthritis, and the patient successfully underwent dual treatment with ursodeoxycholic acid and the anti-tumour necrosis factor-alpha agent adalimumab. In the second case, the predominant condition was, initially, an antimitochondrial antibody-negative primary biliary cirrhosis with progressive course towards end-stage liver disease; the patient then developed either antimitochondrial antibody positivity or changes in the biliary tree compatible with primary sclerosing cholangitis. These two cases add information on a controversial issue in the literature, and indicate the importance of recognizing a possible overlap syndrome to optimize treatment. Copyright © 2015. Published by Elsevier Ltd.
    Digestive and Liver Disease 02/2015; 47(5). DOI:10.1016/j.dld.2015.02.002 · 2.96 Impact Factor
  • G. Sansoè · M. Aragno · R. Mastrocola · F. Rosina · M. Parola ·

    Digestive and Liver Disease 02/2015; 47:e19. DOI:10.1016/j.dld.2015.01.044 · 2.96 Impact Factor
  • G C Actis · R Pellicano · F Rosina ·

    Minerva gastroenterologica e dietologica 09/2014; 60(3):201.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs), a class of small non-coding RNAs, are fundamental for the post-transcriptional regulation of gene expression. Altered expression of miRNAs has been detected in cancers, not only in primary tissue but also in easily obtainable specimens like plasma and stools. miRNA expression is known to be modulated by diet (micro and macronutrients, phytochemicals) and possibly by other lifestyle factors; however, such influence has not yet been exhaustively explored in humans. In the present study, we analysed the expression levels of a panel of seven human miRNAs in plasma and stool samples of a group of 24 healthy individuals characterised by different dietary habits (eight vegans, eight vegetarians and eight subjects with omnivorous diet, all groups with similar age and sex distribution). The dual aim of the study was to identify possible differences in miRNA expression due to diet (or other lifestyle factors recorded from questionnaires) and to compare results in both types of specimens. miR-92a was differentially expressed in both plasma and stool samples and with the same trend, among the three groups with different diets (P = 0.0002 and P = 0.02, respectively, with expression levels of vegans>vegetarians>omnivores). miR-92a was also associated with low body mass index (P = 0.04 and P = 0.05, respectively) in both types of specimens, and with several dietary factors. Other analysed miRNAs (miR-16, miR-21, mir-34a and miR-222) were associated with dietary and lifestyle factors, but not consistently in both stool and plasma. Our pilot study provides the first evidence of miRNA modulation by diet and other factors, that can be detected consistently in both plasma and stools samples.
    Mutagenesis 09/2014; 29(5):385-91. DOI:10.1093/mutage/geu028 · 2.79 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: tBackground: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostlyderived from treatment of selected patients enrolled in clinical trials. This study aimed to assess theeffectiveness of Peg-interferon/ribavirin therapy in “real world” chronic hepatitis C patients in Italy.Methods: Independent observational multicentre study including consecutive patients receiving Peg-interferon/ribavirin in the 18 months before (retrospective phase) and after (prospective phase) the startof the study.Results: 4176 patients were eligible. The final study population consisted of 2051 patients in the retro-spective and 2073 in the prospective phase.Sustained virological response was achieved by 1036 patients (50.5%) during the retrospective phase:325 were genotypes 1/4 (34.1%) and 684 were genotypes 2/3 (67.2%) and by 800 patients (38.6%) duringthe prospective phase: 300 were genotypes 1/4 (28.4%) and 473 were genotypes 2/3 (51.5%).During multivariate analysis genotypes 2/3 were significantly associated with higher sustained viro-logical response rates; cirrhosis and �-glutamil-transpeptidase >2 times the normal limit were associatedwith poorer response.Conclusions: The response to Peg-interferon/ribavirin therapy in “real world” clinical practice is distinctlylower than in registration trials. The difference in response rates was more pronounced among easy-to-treat than among difficult-to-treat hepatitis C virus genotypes.© 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved
    Digestive and Liver Disease 09/2014; 46(9). DOI:10.1016/j.dld.2014.05.014 · 2.96 Impact Factor
  • Source
    Giovanni C Actis · Rinaldo Pellicano · Floriano Rosina ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Current knowledge on inflammatory bowel disease (IBD) is mainly endorsed by controlled trials and epidemiologic studies. Yet, we seldom look at the messages from real-world practice. Among a patient population followed since 2008, we looked at an unselected sample of 64 IBD patients [26 Crohn's disease (CD) and 38 ulcerative colitis (UC)] who had been seen as out-patients in the last year. Inducing remission, mesalamines (86% for UC/69% for CD/33%-16% as MMX formulation) prevailed as prescriptions; steroids (55%/19% for UC/CD) ranked second. Prescription of third-party drugs (antibiotics, NSAIDs, biologics) and adherence, were issues in the maintenance. 34% of CD, and 23% of UC patients showed accompanying immunologic diseases: CD-associated familiar psoriasis (4:9) ranked first. Main Message. The association between IBD (CD mainly) and psoriasis, now found in our practice, matches current basic science gathering IBD together with psoriasis (and perhaps chronic respiratory disease) under the comprehensive term "barrier organ disease" wherein an epithelial surface with sensor systems rules contacts between outer antigens and a reactive underneath tissue, with the balance between inflammation and quiescence kept at any time by mucosal permeability. IBD is thus viewed as a polyfactorial/polygenic/syndromic disorder, embedded into a galaxy of immune conditions offering multiple points of attack. This mindset of splitting the IBDs into pathogenic categories may allow overcoming the uniformly targeting of a single cytokine by biological drugs, in favor of demarcating the boundaries between different disease-subtype-specific indications, and paving the way to future personalized strategies.
    08/2014; 5(3):169-74. DOI:10.4292/wjgpt.v5.i3.169
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostly derived from treatment of selected patients enrolled in clinical trials. This study aimed to assess the effectiveness of Peg-interferon/ribavirin therapy in "real world" chronic hepatitis C patients in Italy.
    Digestive and Liver Disease 05/2014; · 2.96 Impact Factor
  • Source
    Giovanni Clemente Actis · Rinaldo Pellicano · Floriano Rosina ·

    Journal of Pharmacology and Pharmacotherapeutics 04/2014; 5(2):151-2. DOI:10.4103/0976-500X.130071
  • M. Ayoubi · F. Castellino · G. Sansoe · M. Berrutti · N. Leone · F. Rosina ·

    Digestive and Liver Disease 03/2014; 46:S134. DOI:10.1016/S1590-8658(14)60398-4 · 2.96 Impact Factor
  • M. Ayoubi · F. Castellino · G. Sansoe · F. Rosina ·

    Digestive and Liver Disease 03/2014; 46:S134. DOI:10.1016/S1590-8658(14)60397-2 · 2.96 Impact Factor
  • Giovanni C Actis · Rinaldo Pellicano · Maurizio Fadda · Floriano Rosina ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To explore the type and frequency of the unwanted effects following use of non-steroidal antiinflammatory drugs (NSAIDs) and antibiotics in a gastroenterological out-patient setting. Methods: We analyzed a gastroenterological database which includes 151 inflammatory bowel disease (IBD) patients followed between January 2008 and December 2009. The key-words included NSAIDs and antibiotics. Results: Of 19 cases treated with NSAIDs, 8 displayed convincing evidence linking them with the subsequent development of IBD. Of 44 antibiotic mentions, 7 documents alluded to macrolide prescriptions, which were followed by induction or relapse of IBD in 5; all of the newly diagnosed cases of IBD were endoscopically proven, and one ran a fulminant course requiring emergency colectomy; 4 of 5 prescriptions of amoxycillin/clavulanic acid were accompanied by toxicity (three hepatitides and one reactivated IBD). Overall, the frequency of unwanted effects was 36% for both NSAIDs and antibiotics. Conclusion: We suggest that NSAIDs and antibiotics (specifically of the macrolide structure) can induce gut and hepatic damage, significantly enhancing co-morbidities in gastroenterologic out-patients, with break of cost-containment guidelines. Therefore, caution is advisable in prescribing NSAIDs and antibiotics in this setting. Though retrospective and possibly biased, the current data coincide with both bench work and epidemiological evidence.
    01/2014; 9(2):133-7. DOI:10.2174/1574886309666140120095233
  • Giovanni C Actis · Floriano Rosina ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The pathogenesis of the two inflammatory bowel diseases (IBDs) phenotypes ulcerative colitis (UC) and Crohn's disease (CD) has remained elusive, thus frustrating attempts at defining a cure. IBD often presents as a complex inflammatory process wherein colon lesions (UC) or widespread ulceration and fissure (CD) might be accompanied by ancillary extra-intestinal manifestations involving the eye, skin, joints or liver, but also by full-blown "autoimmune" disorders from psoriasis and multiple sclerosis to rheumatoid arthritis; attempts at unraveling a link or a hierarchical order in these entities have proven almost fruitless. More recently, the input of genetics has suggested that the IBDs might be multi-organ inflammatory processes, elicited by a large number of low-penetrance susceptibility genes, with environmental factors needed to induce full-blown disease. At a noteworthy exception to this rule, the description of the nucleotide-oligomerization domain (NOD) gene mutations in CD came at the beginning of the 2000s: the NOD-LRR are part of a highly conserved microbial sensor system which respond to bacterial peptidoglycans by mounting an inflammatory response. At least in Caucasian patients, the prevalently loss-of-function mutation of NOD permitted to unexpectedly define CD as an immune deficiency state, and upon its recent description in apparently unrelated disorders such as the Blau syndrome (a granulomatous pediatric syndrome), and perhaps in psoriasis and chronic obstructive pulmonary disorders, has contributed to revolutionize our view of IBD and CD in particular. The latter affection, together with psoriasis and chronic pulmonary disease can now be included into a newly identified category named "barrier organ disease", wherein a barrier organ is defined as a large mucosal or epithelial surface with an abundant metagenomic microbial population and an underneath reactive tissue, the whole structure being in contact with the outer environment and capable to react to it. Personalized treatments and empowerment of research across different disease phenotypes should be the advantages of this novel mindset.
    08/2013; 4(3):41-6. DOI:10.4292/wjgpt.v4.i3.41
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Genome-wide association studies (GWAS) have successfully identified several loci associated with primary biliary cirrhosis (PBC) risk. Pathway analysis complements conventional GWAS analysis. We applied the recently developed linear combination test for pathways to datasets drawn from independent PBC GWAS in Italian and Canadian subjects. Of the Kyoto Encyclopedia of Genes and Genomes and BioCarta pathways tested, 25 pathways in the Italian dataset (449 cases, 940 controls) and 26 pathways in the Canadian dataset (530 cases, 398 controls) were associated with PBC susceptibility (P<0.05). After correcting for multiple comparisons, only the eight most significant pathways in the Italian dataset had FDR <0.25 with tumor necrosis factor/stress-related signaling emerging as the top pathway (P=7.38 × 10(-4), FDR=0.18). Two pathways, phosphatidylinositol signaling and hedgehog signaling, were replicated in both datasets (P<0.05), and subjected to two additional complementary pathway tests. Both pathway signals remained significant in the Italian dataset on modified gene set enrichment analysis (P<0.05). In both GWAS, variants nominally associated with PBC were significantly overrepresented in the phosphatidylinositol pathway (Fisher exact P<0.05). These results point to established and novel pathway-level associations with inherited predisposition to PBC that, on further independent replication and functional validation, may provide fresh insights into PBC etiology.Genes and Immunity advance online publication, 7 February 2013; doi:10.1038/gene.2013.1.
    Genes and immunity 02/2013; 14(3). DOI:10.1038/gene.2013.1 · 2.91 Impact Factor
  • Giovanni C Actis · Sonia Tarallo · Floriano Rosina ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Colitis-associated cancer represents a long-standing problem, with two new factors adding to its importance: the diffusion of inflammatory bowel disease in developing countries, and the increased availability of effective drugs that control ulcerative colitis delaying or abrogating the need for a curative colectomy. The consolidated evidence that inflammation is the unique variable that factors in colitic cancer development has conferred impetus to the search and release of anti-inflammatory/immune suppressive molecules to pursue the goal of cancer chemoprevention. Cutting-edge research has provided breakthrough insights into the mechanism of the chemopreventive actions of mesalamines, thiopurines, and probiotics, and we expand on these topics. Despite these advancements, bedside evidence is still mixed and calls for further scrutiny. Nowadays, the clinician must continue to rely on classic preventive measures such as surveillance colonoscopy, and the early and aggressive use of drugs that permit to keep the degree of mucosal inflammation to a minimum.
    11/2012; 12(1). DOI:10.2174/1871528111312010001
  • Giovanni C Actis · Floriano Rosina · Rinaldo Pellicano · Mario Rizzetto ·
    [Show abstract] [Hide abstract]
    ABSTRACT: We studied the toxicity of cyclosporin (CsA), azathioprine, and mesalamine in 94 patients with inflammatory bowel disease (IBD). 63 treatments with CsA (2mg/kg intravenously or 5 mg/kg orally); 57 with azathioprine (2 mg/kg); and 44 with mesalamine (3.2-4.8 gr) were included. After induction, oral CsA was continued for 6 months, azathioprine for a median of 14 months (range 1-201 mos), mesalamine until tolerated. CsA toxicity frequency 25%: withdrawal and colectomy in 3 cases. AZA toxicity rate: 43% with an overall time-to-onset of a median of 6 months (range 1-60 mos); withdrawal and colectomy in 7 cases; 62% of the events were other than leukopenia. Mesalamine toxicity rates: (13.6%) with one colectomy. Toxicity-related withdrawal of conventional IBD treatments is significant and leads to colectomy in ulcerative colitis. 50% of the thiopurine toxicities outrange the predicting power of the available pharmacogenomic assays; mesalamine often causes allergic lung dysfunction. Efforts are warranted to optimize this conventional treatment of IBD.
    05/2012; 7(3):209-13. DOI:10.2174/157488412800958730

  • Journal of Hepatology 04/2012; 44:S12. DOI:10.1016/S1590-8658(12)60036-X · 11.34 Impact Factor
  • E Tarabra · G.C. Actis · M Fadda · P De Paolis · A Comandone · R Coda · F Rosina ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Representing the second cause of cancer-related death after lung cancer in men and breast cancer in women, colorectal cancer (CRC) is a major health problem in Italy. Obesity is reckoned to favor CRC; however, the underlying mechanisms are unclear. Recently, a single nucleotide polymorphism (SNP) in the fat mass and obesity associated (FTO) gene was found to be significantly associated with obesity. To establish whether the FTO SNP rs9939609 may represent a risk factor for CRC and adenoma in the Italian population. 1,037 subjects were enrolled in the study and divided in 3 groups: CRC (341 pts., M/F=197/144, mean age=65.17±11.16 years), colorectal adenoma (385 pts., M/F=247/138, mean age=62.49±13.01 years), healthy controls (311 pts., M/F=150/161, mean age=57.31±13.84 years). DNA was extracted from whole blood, and stored frozen for rs9939609 genotyping by real-time PCR. The frequency of the obesity-associated mutated A allele (AA+AT) on the FTO gene was 69.77% among controls, and 71.85% and 65.71% respectively among CRC and polyp patients. Compared to control subjects the AA+AT genotype had no significant effect on the risk for either CRC (OR=1.106; CI 95%=0.788-1.550; p=0.561) or colorectal adenomas (OR=0.830; CI 95%=0.602-1.144; p=0.255). We did not observe any association between the AA genotype and CRC/polyp localization and age at diagnosis. As measured in a patient subset, carriership of the risk alleles did not reflect in a significantly altered BMI. The obesity-linked FTO variants do not play a significant role in modulating the colorectal cancer risk in the Italian population.
    European Journal of Internal Medicine 01/2012; 23(1):65-9. DOI:10.1016/j.ejim.2011.07.011 · 2.89 Impact Factor
  • Giovanni C Actis · Rinaldo Pellicano · Sonia Tarallo · Floriano Rosina ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Traditional knowledge of clinical, laboratorial, and endoscopic orders regarding ulcerative colitis and Crohn's disease has begun to be implemented by the revolutionary data from genetic studies. Ever since many decades ago it has been clear that inflammatory bowel diseases are complex multifactorial disorders wherein gut-confined and/or environmental factors must synergize with genetic components to effect the full-blown disorder. The sequencing of the human genome and the generation of public resources of single nucleotide polymorphisms permitted the conduction of powerful population based genome-wide association studies. The latter have increased the number of the identified susceptibility loci to 99. In this review we touched on two pathways that make true susceptibility genes for inflammatory bowel diseases; gene loci that confer specific risk for ulcerative colitis and Crohn's disease were discussed in detail.
    12/2011; 10(6):447-54. DOI:10.2174/187152811798104926

Publication Stats

3k Citations
1,189.49 Total Impact Points


  • 2008-2015
    • Presidio Sanitario San Camillo, Torino
      Torino, Piedmont, Italy
  • 1989-2006
    • Università degli Studi di Torino
      • Department of Medical Science
      Torino, Piedmont, Italy
  • 2000
    • University of Oslo
      Kristiania (historical), Oslo, Norway
  • 1999
    • University of California, Davis
      • Division of Rheumatology/Allergy/Clinical Immunology
      Davis, CA, United States
  • 1997
    • Università degli Studi di Bari Aldo Moro
      Bari, Apulia, Italy
  • 1995-1996
    • Istituto Nazionale Tumori "Fondazione Pascale"
      Napoli, Campania, Italy
  • 1991
    • Ospedale San Giovanni Battista, ACISMOM
      Torino, Piedmont, Italy